We are live on ! Find out more
ARIA

Ariad Pharmaceuticals Inc
ARIA

Delisted

ARIA was delisted on the 15th of February, 2017.

175 hedge funds and large institutions have $801M invested in Ariad Pharmaceuticals Inc in 2015 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 52 increasing their positions, 62 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more call options, than puts

Call options by funds: $14.3M | Put options by funds: $12.5M

0% more funds holding in top 10

Funds holding in top 10: 55 (0)

8% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 24

1% less funds holding

Funds holding: 177175 (-2)

16% less repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 62

31% less capital invested

Capital invested by funds: $1.16B → $801M (-$358M)

Holders
175
Holders Change
-2
Holders Change %
-1.13%
% of All Funds
4.89%
Holding in Top 10
5
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.14%
New
22
Increased
52
Reduced
62
Closed
24
Calls
$14.3M
Puts
$12.5M
Net Calls
+$1.83M
Net Calls Change
+$2.71M
Name Holding Trade Value Shares
Change
Change in
Stake
OAM
51
Oxford Asset Management
United Kingdom
$1.73M -$3.64M -472,570 -61%
Morgan Stanley
52
Morgan Stanley
New York
$1.68M -$2.3M -298,908 -51%
Group One Trading
53
Group One Trading
Illinois
$1.5M +$1.31M +170,254 +197%
QIM
54
Quantitative Investment Management
Virginia
$1.38M +$1.83M +236,900 New
Swiss National Bank
55
Swiss National Bank
Switzerland
$1.37M +$240K +31,100 +15%
UBS Group
56
UBS Group
Switzerland
$1.35M -$151K -19,604 -8%
Deutsche Bank
57
Deutsche Bank
Germany
$1.35M -$3.82M -496,216 -68%
EEG
58
E.E. Geduld
$1.23M -$578K -75,000 -26%
PP
59
PDT Partners
New York
$1.23M +$1.62M +209,800 New
1CM
60
1492 Capital Management
Wisconsin
$1.18M +$1.08M +140,000 +224%
IHM
61
Iguana Healthcare Management
New York
$1.06M +$963K +125,000 New
SM
62
Sabby Management
Florida
$987K +$28.7K +3,730 +2%
BA
63
BlackRock Advisors
Delaware
$959K -$2.2M -285,506 -63%
New York State Common Retirement Fund
64
New York State Common Retirement Fund
New York
$956K -$76.5K -9,935 -6%
RhumbLine Advisers
65
RhumbLine Advisers
Massachusetts
$944K +$23.1K +2,995 +2%
ProShare Advisors
66
ProShare Advisors
Maryland
$935K -$90.5K -11,743 -7%
CSS
67
Cubist Systematic Strategies
Connecticut
$920K -$136K -17,594 -10%
D.E. Shaw & Co
68
D.E. Shaw & Co
New York
$911K -$196K -25,438 -14%
BG
69
BlackRock Group
United Kingdom
$904K -$286K -37,061 -19%
MIG
70
Mariner Investment Group
New York
$834K
Arrowstreet Capital
71
Arrowstreet Capital
Massachusetts
$831K +$753K +97,721 +219%
UBS AM
72
UBS AM
Illinois
$829K +$249K +32,380 +30%
State Board of Administration of Florida Retirement System
73
State Board of Administration of Florida Retirement System
Florida
$796K
SC
74
Skylands Capital
Wisconsin
$774K
SGAM
75
Steinberg Global Asset Management
Florida
$748K +$585K +75,906 +145%

ARIA Hedge Fund Activity: Q3 2015 in Review

175 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Ariad Pharmaceuticals Inc (ARIA) for Q3 2015, worth a combined $801M — down 31% from $1.16B a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of ARIA and 22 opened new positions — a net loss of 2 holders — while 62 trimmed existing stakes and 52 added.

The largest buyer was Putnam Investments, adding an estimated $86.4M. The largest seller was Discovery Capital Management, exiting entirely with an estimated $43.9M sold.

  • 175 institutional investors held Ariad Pharmaceuticals Inc (ARIA) as of Q3 2015, down from 177 in Q2 2015.
  • Funds reported $801M of Ariad Pharmaceuticals Inc stock for Q3 2015, down 31% quarter-over-quarter.
  • 22 funds opened new Ariad Pharmaceuticals Inc positions in Q3 2015 and 24 closed out, a net change of -2 holders.
  • The largest Ariad Pharmaceuticals Inc buyer in Q3 2015 was Putnam Investments, an estimated $86.4M added.
  • The largest Ariad Pharmaceuticals Inc seller in Q3 2015 was Discovery Capital Management, an estimated $43.9M sold.

Based on aggregated 13F filings for Q3 2015.